69 related articles for article (PubMed ID: 22178065)
1. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.
Van De Craen B; Scroyen I; Vranckx C; Compernolle G; Lijnen HR; Declerck PJ; Gils A
Thromb Res; 2012 Apr; 129(4):e126-33. PubMed ID: 22178065
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.
Van De Craen B; Scroyen I; Abdelnabi R; Brouwers E; Lijnen HR; Declerck PJ; Gils A
Thromb Res; 2011 Jul; 128(1):68-76. PubMed ID: 21392818
[TBL] [Abstract][Full Text] [Related]
3. Biochemical importance of glycosylation of plasminogen activator inhibitor-1.
Gils A; Pedersen KE; Skottrup P; Christensen A; Naessens D; Deinum J; Enghild JJ; Declerck PJ; Andreasen PA
Thromb Haemost; 2003 Aug; 90(2):206-17. PubMed ID: 12888867
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
[TBL] [Abstract][Full Text] [Related]
5. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1.
Montes R; Declerck PJ; Calvo A; Montes M; Hermida J; Muñoz MC; Rocha E
Thromb Haemost; 2000 Jul; 84(1):65-70. PubMed ID: 10928472
[TBL] [Abstract][Full Text] [Related]
6. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
7. Characterization of recombinant rat plasminogen activator inhibitor-1 and development of immunological tools for its quantitation.
Ngo TH; Verheyen S; Knockaert I; Declerck PJ
J Pharm Belg; 1997; 52(4):165-6. PubMed ID: 9316343
[TBL] [Abstract][Full Text] [Related]
8. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitors.
Gils A
Verh K Acad Geneeskd Belg; 2006; 68(3):179-98. PubMed ID: 16796017
[TBL] [Abstract][Full Text] [Related]
9. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
Ngo TH; Zhou Y; Stassen JM; Declerck PJ
Thromb Haemost; 2002 Aug; 88(2):288-93. PubMed ID: 12195702
[TBL] [Abstract][Full Text] [Related]
10. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
11. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
Hagège J; Delarue F; Peraldi MN; Sraer JD; Rondeau E
Lab Invest; 1994 Dec; 71(6):828-37. PubMed ID: 7807964
[TBL] [Abstract][Full Text] [Related]
12. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
Debrock S; Declerck PJ
Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
14. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
15. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
[TBL] [Abstract][Full Text] [Related]
16. Use of mouse models to study plasminogen activator inhibitor-1.
Declerck PJ; Gils A; De Taeye B
Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
[TBL] [Abstract][Full Text] [Related]
17. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
[TBL] [Abstract][Full Text] [Related]
18. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
[TBL] [Abstract][Full Text] [Related]
19. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization and application of monoclonal antibodies against PAI-1.
Ding H; Wu X; Zhou X; Zhu Y; Song H
Chin J Biotechnol; 1994; 10(2):121-8. PubMed ID: 7803688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
